Vimta Labs Boosts Employee Ownership with New Stock Option Allotment

Vimta Labs Limited , a prominent player in the Indian stock market, has taken a significant step to enhance employee engagement and ownership. The company recently announced the allotment of equity shares under its Employee Stock Option Plan (ESOP), demonstrating its commitment to aligning employee interests with corporate growth.

Key Details of the Allotment

Aspect	Details
Number of Shares Allotted	94,369
Face Value per Share	₹2
Allotment Date	November 17, 2025
ESOP Scheme	Employee Stock Option Plan 2021

Impact on Share Capital

The allotment of these equity shares has resulted in a notable increase in Vimta Labs' paid-up share capital:

Capital Status	Amount (in ₹)
Previous Paid-up Capital	8,90,81,640.00
New Paid-up Capital	8,92,70,378.00
Increase	1,88,738.00

This move by Vimta Labs underscores the company's strategy to foster a sense of ownership among its employees. By offering equity shares through the ESOP, the company aims to motivate and retain talent, aligning the interests of employees with those of shareholders.

It's worth noting that the newly allotted shares will rank pari-passu with the existing equity shares of the company. This means that the new shares will carry the same rights and privileges as the current outstanding shares, ensuring equal treatment for all shareholders.

The implementation of such employee stock option plans is a common practice among companies looking to create a more engaged and committed workforce. For Vimta Labs, this allotment could potentially lead to increased employee productivity and loyalty, which may, in turn, contribute to the company's long-term growth and success in the competitive Indian market landscape.

As the Indian stock market continues to evolve, moves like these by Vimta Labs highlight the increasing focus on employee welfare and engagement as key drivers of corporate performance and shareholder value.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.52%	-4.57%	-9.03%	+20.57%	+61.15%	+827.73%

Vimta Labs Limited (ISIN: INE579C01029) has reported its highest-ever quarterly sales revenue of INR 104.5 crore in Q2 FY26, marking a significant 22.3% year-on-year growth. The company's strong performance was primarily driven by its pharmaceutical research and testing services, as well as food testing services.

Financial Highlights

Metric	Q2 FY26	Q2 FY25	YoY Growth
Total Income	1,045.00	854.00	22.3%
EBITDA	369.00	306.00	20.6%
EBITDA Margin	35.3%	35.8%	-50 bps
Profit After Tax	199.00	170.00	17.1%
PAT Margin	19.1%	19.9%	-80 bps

All financial figures in INR million, except percentages

Key Business Segments

Vimta Labs' revenue mix for Q2 FY26 was as follows:

Pharmaceutical services: ~65% of total revenue
Food testing services: ~20% of total revenue
Environmental and electronics testing services: Remainder

Operational Highlights

The company's clinical research division successfully completed a WHO audit, reflecting its commitment to maintaining strong quality and compliance standards.
Vimta Labs has commenced operations with a new testing chamber installed at its life sciences facility, expanding capacity in the electrical and electronics division.
The company is progressing with its biologics contract research and development services project, with the facility expected to be ready by the end of Q3 FY26 and commercialization anticipated in Q1 FY27.

Expansion and Future Outlook

Vimta Labs has incurred a capex of INR 47 crore during the first half of FY26.
The company plans to spend approximately INR 25 crore on biologics expansion this year.
Management remains confident about achieving its targeted exit run rate of around INR 500 crore for the current financial year.

Market Position and Competition

Vimta Labs competes with both domestic and international players across its various service segments:

In food testing, competitors include multinational companies like SGS, Eurofins, Intertek, and Bureau Veritas.
For pharmaceutical services, the company faces competition from both domestic and international Contract Research Organizations (CROs).

The company's strategy involves expanding its global reach and integrating its services to provide end-to-end solutions, particularly in the growing biologics and large molecule research and development support services.

Vimta Labs maintains a strong balance sheet with no debt and cash and cash equivalents, including bank balances, of INR 545.00 million as of September 30, 2025.

As the pharmaceutical and food testing industries continue to grow, Vimta Labs is well-positioned to capitalize on emerging opportunities, supported by its expanded capacities and focus on technological advancements in testing methodologies.